Antitumor Activities and Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23,469 in the 7,12-Dimethylbenz(a)anthracene-Induced Rat Mammary Tumor System

Research output: Contribution to journalArticle

Abstract

This study compares the antitumor activities of the nonsteroidal antiestrogens α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-methoxy-α‘-nitrostilbene (CI628) and cis-{3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol} (U23,469) with their demethylated metabolite forms in the dimethylbenz(a)anthracene-induced rat mammary tumor system. Since these demethylated forms are generated during the action of the parent antiestrogens in vivo and are selectively accumulated in the nuclear estrogen receptor fraction in preference to the parent compound, we investigated whether direct administration of the metabolites might prove more effective than administration of the parent antiestrogens in eliciting tumor regression. We have therefore compared the potencies of the parent antiestrogens and their demethylated forms α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-hydroxy-α -nitrostilbene (CI628M) and cis-{3-[p-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthyl)-phenoxy]-1,2-propanediol} (U23,469M) in stimulating the regression of established dimethylbenz(a)anthracene-induced mammary tumors; and we have monitored the effects of these antiestrogens on estrogen receptors and the enzyme peroxidase as a specific marker for estrogen action in mammary tumors and in uteri of tumor-bearing animals. In mammary tumor cytosol in vitro, the antiestrogens competed with [3H]estradiol for binding to estrogen receptor with affinities of 113% (CI628M), 5% (CI628), 31% (U23,469M), and 0.6% (U23,469), where the affinity of estradiol is considered to be 100%. However, all four antiestrogens were equally effective as antagonists of tumor growth in vivo. Administration of 25 or 100 μg daily of either parent (CI628 and U23,469) or the demethylated (CI628M and U23,469M) antiestrogens was able to elicit the regression of the majority of dimethylbenz(a)anthracene tumors, while low doses (2.5 μg/day) of any of these four compounds had no effect on tumor growth. The 25- and 1OChpg doses of antiestrogens markedly reduced tumor cytoplasmic estrogen receptor levels, but they failed to elevate significantly tumor peroxidase activity. Uterine weights were significantly decreased below the diestrus controls following treatment with 25- or 100-μg daily dosages of the antiestrogens; and these treatments resulted in the nuclear localization of approximately 80% of total estrogen receptors. Uterine peroxidase activity, which was high in diestrus control females.

Original languageEnglish (US)
Pages (from-to)1257-1262
Number of pages6
JournalCancer Research
Volume41
Issue number4
StatePublished - Apr 1 1981

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Breast Neoplasms
Neoplasms
Peroxidase
Diestrus
Estradiol
anthracene
ovothiol A
CI 628M
Propylene Glycol
Cytoplasmic and Nuclear Receptors
Growth
Cytosol
Uterus
Estrogens
Weights and Measures

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{cfa4f8eb4c924199896f33f13bdbe727,
title = "Antitumor Activities and Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23,469 in the 7,12-Dimethylbenz(a)anthracene-Induced Rat Mammary Tumor System",
abstract = "This study compares the antitumor activities of the nonsteroidal antiestrogens α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-methoxy-α‘-nitrostilbene (CI628) and cis-{3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol} (U23,469) with their demethylated metabolite forms in the dimethylbenz(a)anthracene-induced rat mammary tumor system. Since these demethylated forms are generated during the action of the parent antiestrogens in vivo and are selectively accumulated in the nuclear estrogen receptor fraction in preference to the parent compound, we investigated whether direct administration of the metabolites might prove more effective than administration of the parent antiestrogens in eliciting tumor regression. We have therefore compared the potencies of the parent antiestrogens and their demethylated forms α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-hydroxy-α -nitrostilbene (CI628M) and cis-{3-[p-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthyl)-phenoxy]-1,2-propanediol} (U23,469M) in stimulating the regression of established dimethylbenz(a)anthracene-induced mammary tumors; and we have monitored the effects of these antiestrogens on estrogen receptors and the enzyme peroxidase as a specific marker for estrogen action in mammary tumors and in uteri of tumor-bearing animals. In mammary tumor cytosol in vitro, the antiestrogens competed with [3H]estradiol for binding to estrogen receptor with affinities of 113{\%} (CI628M), 5{\%} (CI628), 31{\%} (U23,469M), and 0.6{\%} (U23,469), where the affinity of estradiol is considered to be 100{\%}. However, all four antiestrogens were equally effective as antagonists of tumor growth in vivo. Administration of 25 or 100 μg daily of either parent (CI628 and U23,469) or the demethylated (CI628M and U23,469M) antiestrogens was able to elicit the regression of the majority of dimethylbenz(a)anthracene tumors, while low doses (2.5 μg/day) of any of these four compounds had no effect on tumor growth. The 25- and 1OChpg doses of antiestrogens markedly reduced tumor cytoplasmic estrogen receptor levels, but they failed to elevate significantly tumor peroxidase activity. Uterine weights were significantly decreased below the diestrus controls following treatment with 25- or 100-μg daily dosages of the antiestrogens; and these treatments resulted in the nuclear localization of approximately 80{\%} of total estrogen receptors. Uterine peroxidase activity, which was high in diestrus control females.",
author = "Rorke, {Ellen A.} and Katzenellenbogen, {Benita S}",
year = "1981",
month = "4",
day = "1",
language = "English (US)",
volume = "41",
pages = "1257--1262",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Antitumor Activities and Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23,469 in the 7,12-Dimethylbenz(a)anthracene-Induced Rat Mammary Tumor System

AU - Rorke, Ellen A.

AU - Katzenellenbogen, Benita S

PY - 1981/4/1

Y1 - 1981/4/1

N2 - This study compares the antitumor activities of the nonsteroidal antiestrogens α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-methoxy-α‘-nitrostilbene (CI628) and cis-{3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol} (U23,469) with their demethylated metabolite forms in the dimethylbenz(a)anthracene-induced rat mammary tumor system. Since these demethylated forms are generated during the action of the parent antiestrogens in vivo and are selectively accumulated in the nuclear estrogen receptor fraction in preference to the parent compound, we investigated whether direct administration of the metabolites might prove more effective than administration of the parent antiestrogens in eliciting tumor regression. We have therefore compared the potencies of the parent antiestrogens and their demethylated forms α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-hydroxy-α -nitrostilbene (CI628M) and cis-{3-[p-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthyl)-phenoxy]-1,2-propanediol} (U23,469M) in stimulating the regression of established dimethylbenz(a)anthracene-induced mammary tumors; and we have monitored the effects of these antiestrogens on estrogen receptors and the enzyme peroxidase as a specific marker for estrogen action in mammary tumors and in uteri of tumor-bearing animals. In mammary tumor cytosol in vitro, the antiestrogens competed with [3H]estradiol for binding to estrogen receptor with affinities of 113% (CI628M), 5% (CI628), 31% (U23,469M), and 0.6% (U23,469), where the affinity of estradiol is considered to be 100%. However, all four antiestrogens were equally effective as antagonists of tumor growth in vivo. Administration of 25 or 100 μg daily of either parent (CI628 and U23,469) or the demethylated (CI628M and U23,469M) antiestrogens was able to elicit the regression of the majority of dimethylbenz(a)anthracene tumors, while low doses (2.5 μg/day) of any of these four compounds had no effect on tumor growth. The 25- and 1OChpg doses of antiestrogens markedly reduced tumor cytoplasmic estrogen receptor levels, but they failed to elevate significantly tumor peroxidase activity. Uterine weights were significantly decreased below the diestrus controls following treatment with 25- or 100-μg daily dosages of the antiestrogens; and these treatments resulted in the nuclear localization of approximately 80% of total estrogen receptors. Uterine peroxidase activity, which was high in diestrus control females.

AB - This study compares the antitumor activities of the nonsteroidal antiestrogens α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-methoxy-α‘-nitrostilbene (CI628) and cis-{3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol} (U23,469) with their demethylated metabolite forms in the dimethylbenz(a)anthracene-induced rat mammary tumor system. Since these demethylated forms are generated during the action of the parent antiestrogens in vivo and are selectively accumulated in the nuclear estrogen receptor fraction in preference to the parent compound, we investigated whether direct administration of the metabolites might prove more effective than administration of the parent antiestrogens in eliciting tumor regression. We have therefore compared the potencies of the parent antiestrogens and their demethylated forms α-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-hydroxy-α -nitrostilbene (CI628M) and cis-{3-[p-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthyl)-phenoxy]-1,2-propanediol} (U23,469M) in stimulating the regression of established dimethylbenz(a)anthracene-induced mammary tumors; and we have monitored the effects of these antiestrogens on estrogen receptors and the enzyme peroxidase as a specific marker for estrogen action in mammary tumors and in uteri of tumor-bearing animals. In mammary tumor cytosol in vitro, the antiestrogens competed with [3H]estradiol for binding to estrogen receptor with affinities of 113% (CI628M), 5% (CI628), 31% (U23,469M), and 0.6% (U23,469), where the affinity of estradiol is considered to be 100%. However, all four antiestrogens were equally effective as antagonists of tumor growth in vivo. Administration of 25 or 100 μg daily of either parent (CI628 and U23,469) or the demethylated (CI628M and U23,469M) antiestrogens was able to elicit the regression of the majority of dimethylbenz(a)anthracene tumors, while low doses (2.5 μg/day) of any of these four compounds had no effect on tumor growth. The 25- and 1OChpg doses of antiestrogens markedly reduced tumor cytoplasmic estrogen receptor levels, but they failed to elevate significantly tumor peroxidase activity. Uterine weights were significantly decreased below the diestrus controls following treatment with 25- or 100-μg daily dosages of the antiestrogens; and these treatments resulted in the nuclear localization of approximately 80% of total estrogen receptors. Uterine peroxidase activity, which was high in diestrus control females.

UR - http://www.scopus.com/inward/record.url?scp=0019434473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019434473&partnerID=8YFLogxK

M3 - Article

C2 - 6783294

AN - SCOPUS:0019434473

VL - 41

SP - 1257

EP - 1262

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -